Identification of diagnostic candidates in Mendelian disorders using an RNA sequencing-centric approach

• Published in: Genome medicine Vol. 16; no. 1; pp. 110 - 19
• Main Authors: Jaramillo Oquendo, Carolina, Wai, Htoo A, Rich, Wil I, Bunyan, David J, Thomas, N Simon, Hunt, David, Lord, Jenny, Douglas, Andrew G L, Baralle, Diana
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09.09.2024; BioMed Central; BMC
• Subjects: Alternative Splicing; Analysis; Diagnostics; DNA; DNA sequencing; Expression; Gene expression; Genes; Genetic Diseases, Inborn - diagnosis; Genetic Diseases, Inborn - genetics; Genetic testing; Genetics; Genomes; Genomics; Humans; Medical research; Medicine, Experimental; Nucleotide sequence; Nucleotide sequencing; Patients; Phenotypes; Rare disease; Rare diseases; Ribonucleic acid; RNA; RNA sequencing; RNA Splicing; RNA-seq; Sequence Analysis, RNA - methods; Splicing; Transcriptome; Transcriptomes; Transcriptomics; United Kingdom > UK; England; Diagnostics; RNA-seq; Splicing; Expression; Rare disease
• ISSN: 1756-994X; 1756-994X
• DOI: 10.1186/s13073-024-01381-w

RNA sequencing (RNA-seq) is increasingly being used as a complementary tool to DNA sequencing in diagnostics where DNA analysis has been uninformative. RNA-seq enables the identification of aberrant splicing and aberrant gene expression, improving the interpretation of variants of unknown significance (VUSs), and provides the opportunity to scan the transcriptome for aberrant splicing and expression in relevant genes that may be the cause of a patient's phenotype. This work aims to investigate the feasibility of generating new diagnostic candidates in patients without a previously reported VUS using an RNA-seq-centric approach. We systematically assessed the transcriptomic profiles of 86 patients with suspected Mendelian disorders, 38 of whom had no candidate sequence variant, using RNA from blood samples. Each VUS was visually inspected to search for splicing abnormalities. Once aberrant splicing was identified in cases with VUS, multiple open-source alternative splicing tools were used to investigate if they would identify what was observed in IGV. Expression outliers were detected using OUTRIDER. Diagnoses in cases without a VUS were explored using two separate strategies. RNA-seq allowed us to assess 71% of VUSs, detecting aberrant splicing in 14/48 patients with a VUS. We identified four new diagnoses by detecting novel aberrant splicing events in patients with no candidate sequence variants from prior DNA testing (n = 32) or where the candidate VUS did not affect splicing (n = 23). An additional diagnosis was made through the detection of skewed X-inactivation. This work demonstrates the utility of an RNA-centric approach in identifying novel diagnoses in patients without candidate VUSs. It underscores the utility of blood-based RNA analysis in improving diagnostic yields and highlights optimal approaches for such analyses.